---
layout: post
title: What's new for 'ACE inhibitors and cancer' in PubMed
date: '2011-09-24T09:04:00.001-03:00'
author: Francisco H C Felix
tags: 
modified_time: '2011-09-24T09:04:26.410-03:00'
blogger_id: tag:blogger.com,1999:blog-2993346515708552092.post-2252225121396035809
blogger_orig_url: http://pharmak.blogspot.com/2011/09/whats-new-for-ace-inhibitors-and-cancer_24.html
---

This message contains My NCBI what's new results from the National Center for Biotechnology<br /><b>Sender's message: </b> <br />Sent on Saturday, 2011 Sep 24<br />Search <b>angiotensin cancer</b> <br /><div><br /><br /><div><table bgcolor="#CCCCCC"><tbody><tr><td align="center">PubMed Results</td></tr></tbody></table></div><br /><div><table cellpadding="0" cellspacing="5"><tbody><tr><td nowrap="nowrap" valign="top" width="10"></td><td valign="top"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21936625" ref="ordinalpos=1">Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors,  ARBs,  and/or Statins.</a></td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top"><span class="jrnl" title="Cancer investigation">Cancer Invest</span>. 2011 Sep 21. [Epub ahead of print]</td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top">PMID: 21936625 [PubMed - as supplied by publisher]</td></tr><tr><td align="left" valign="top" width="10"><br /></td><td><div><div><div class="artAuthors"><a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Chae%2C+Young+Kwang%29">Young Kwang Chae,<span class="NLM_xref-aff"><sup>1,2,</sup></span></a><a class="ref" href="http://informahealthcare.com/action/showPopup?citid=citart1&amp;id=FN0001&amp;doi=10.3109/07357907.2011.616252">§</a> <a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Valsecchi%2C+Matias+E.%29">Matias E. Valsecchi,<span class="NLM_xref-aff"><sup>2,3,</sup></span></a><a class="ref" href="http://informahealthcare.com/action/showPopup?citid=citart1&amp;id=FN0001&amp;doi=10.3109/07357907.2011.616252">§</a> <a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Kim%2C+Jongoh%29">Jongoh Kim,<span class="NLM_xref-aff"><sup>2,4</sup></span> </a><a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Bianchi%2C+Anabella+Lucca%29">Anabella Lucca Bianchi,<span class="NLM_xref-aff"><sup>2</sup></span> </a><a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Khemasuwan%2C+Danai%29">Danai Khemasuwan,<span class="NLM_xref-aff"><sup>2,5</sup></span> </a><a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Desai%2C+Ajit%29">Ajit Desai,<span class="NLM_xref-aff"><sup>2</sup></span> and </a><a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Tester%2C+William%29">William Tester,<span class="NLM_xref-aff"><sup>2</sup></span></a><br /><div class="fulltext"><span class="institution"><i>Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,</i></span><i> Houston, TX,</i><span class="country"><i> USA,<sup>1</sup></i></span></div><div class="fulltext"><span class="institution"><i>Department of Medicine, Albert Einstein Medical Center,</i></span><i> Philadelphia, PA,</i> <span class="country"><i>USA,<sup>2</sup></i></span></div><div class="fulltext"><span class="institution"><i>Department of Medical Oncology, Thomas Jefferson University Hospital,</i></span><i> Philadelphia, PA, </i><span class="country"><i>USA,<sup>3</sup></i></span></div><div class="fulltext"><span class="institution"><i>Department of Medicine, Balyor College of Medicine, Houston,</i></span><i> TX,</i> <span class="country"><i>USA,<sup>4</sup></i></span></div><div class="fulltext"><span class="institution"><i>Department of Medicine, Cleveland Clinic, Cleveland,</i></span><i> OH,</i> <span class="country"><i>USA<sup>5</sup></i></span></div></div><div class="NLM_author-notes"><div class="first last"><sup>§</sup>Both the authors contributed equally to this study.</div><div class="NLM_corresp">Correspondence to: Young Kwang Chae, MD, MPH, MBA, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, <span class="country">USA</span>. email: <a class="email" href="mailto:ykchae@mdanderson.org">ykchae@mdanderson.org</a></div></div><br /><br /><div class="abstractSection"><div class="first last"><b><i>Background</i>:  Epidemiologic and biochemical evidence suggest a role of statins and  angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor  blockers (ARBs) as anti-neoplastic agents. This study was designed to  evaluate the association between the use of these agents and the risk of  breast cancer recurrence. <i>Methods</i>: We reviewed the medical  records of patients treated for stage II/III breast cancer between 1999  and 2005. Statin and ACE-inhibitors/ARB users were defined as patients  who took these medications for at least 6 months in no evidence of  disease (NED) stage after the initial diagnosis. The primary outcome was  disease-free survival and the secondary was overall survival. The  Kaplan–Meier and Cox proportional hazard models were used. <i>Results</i>:  A total of 703 patients were included. The median and maximal of follow  up was 55 and 118 months, respectively. A total of 168 patients used  ACE-inhibitors/ARBs, 156 patients used statins, and 81 used both.  Univariate analysis showed significant reduction in breast cancer  recurrence among patients who used ACE-inhibitors/ARBs (hazard ratio  (HR) = 0.57; 95% CI: 0.37–0.89; <i>p</i> = .013) or statins (HR = 0.43; 95% CI: 0.26–0.70; <i>p</i> &lt; .001). After adjusting for multiple variables, the use of ACE-inhibitors/ARBs (HR = 0.49; 95% CI: 0.31–0.76; <i>p</i> = .002) and statins (HR = 0.40; 95% CI: 0.24–0.67; <i>p</i> &lt; .001) remained significant and an additive effect was found on those who used both drugs (HR = 0.30 95% CI: 0.15–0.61; <i>p</i> = .001). No association was found regarding overall survival. <i>Conclusions</i>:  The use of ACE-inhibitors/ARBs, statins, and the combination of both  were all associated with a reduced risk of breast cancer recurrence.  This observation should prompt further exploration.</b></div></div><br />Read More: <a href="http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252">http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252</a></div></div></td></tr></tbody></table></div></div>